Loading

Exploring the Uncharted: Rare Diseases, Unintended Consequences of the Inflation Reduction Act, and Demonstrating the Value of These Therapies

June 04, 2024
Breakout Session
Orphan and Rare Disease
30DE
President Biden signed the Inflation Reduction Act into law on August 16, 2022. Almost two years later, our panel will evaluate how the law has impacted rare disease research and development. Our expert panel will provide insights into how the Act's provisions could influence treatment affordability and availability for rare disease patients. Our panel will also touch on how to demonstrate the value of rare disease therapies in the space. This session is designed to spark a constructive dialogue among advocates, policymakers, and other stakeholders.
Speakers
Michele Oshman
Senior Vice President, External Affairs and Head, Patient Advocacy Center of Excellence
Biotechnology Innovation Organization (BIO)
Speakers
Karin Hoelzer, DVM, PhD
Senior Director, Policy and Regulatory Affairs
National Organization for Rare Disorders (NORD)
Kate Jones
Head of Federal Affairs
Alexion, AstraZeneca Rare Disease
Jason Spangler, MD, MPH, FACPM
Chief Executive Officer
Innovation and Value Initiative’s (IVI)
Dionne Stalling
Executive Director
Rare And Black

Sponsored by:

alexion logo
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS